Post-HSCT Brentuximab Vedotin Plus Nivolumab Highly Effective in Hodgkin Lymphoma

(MedPage Today) -- Brentuximab vedotin (Adcetris) in combination with nivolumab (Opdivo) after autologous hematopoietic stem-cell transplantation (HSCT) resulted in improved outcomes in patients with high-risk relapsed or refractory classic Hodgkin...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news